2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-14182
    Vernakalant 794466-70-9 98%
    Vernakalant(RSD-1235) is an investigational mixed ion channel blocker that can terminate acute atrial fibrillation (AF) in humans at 2 to 5 mg/kg and may be more atrial-selective than available agents; in treatment of antiarrhythmic.
    Vernakalant
  • HY-A0043
    Cilazapril 88768-40-5 98%
    Cilazapril is a angiotensin-converting enzyme (ACE) inhibitor used for the treatment of hypertension and congestive heart failure.
    Cilazapril
  • HY-16734
    Amiselimod 942399-20-4 98%
    Amiselimod (MT-1303) is converted to its active metabolite Amiselimod phosphate by sphingosine kinases in vivo. Amiselimod is an orally active and high selectivity sphingosine 1-phosphate receptor-1 (S1P1) agonist, designed to reduce the bradycardia effects associated with fingolimod and other S1P receptor modulators. Amiselimod inhibits chronic colitis via inhibiting infiltration of colitogenic Th1 and Th17 cells into the colon. Amiselimod inhibits lupus nephritis by reducing the infiltration of autoreactive T cells into the kidneys. Amiselimodis promising for research of autoimmune diseases.
    Amiselimod
  • HY-142163
    S62798 2107353-05-7 98%
    S62798 is a selective and potent inhibitor of activated thrombin activatable fibrinolysis inhibitor (TAFIa) with an IC50 value of 6 mM.
    S62798
  • HY-172688
    DSPE-PEG5000-CSTSMLKAC 98%
    DSPE-PEG5000-CSTSMLKAC is a PEG compound which composed of DSPE and a peptide (CSTSMLKAC). CSTSMLKAC is capable of mediating selective homing of phage to ischemic heart tissue. DSPE-PEG5000-CSTSMLKAC can be used for drug delivery.
    DSPE-PEG5000-CSTSMLKAC
  • HY-B1103R
    Hydroxyhexamide (Standard) 3168-01-2
    Hydroxyhexamide (Standard) is an analytical standard for Hydroxyhexamide. This product is intended for research and analytical applications. Hydroxyhexamide is a pharmacologically active metabolite of Acetohexamide, used as a hypoglycemic agents.
    Hydroxyhexamide (Standard)
  • HY-13715AR
    Norepinephrine hydrochloride (Standard) 329-56-6
    Norepinephrine (hydrochloride) (Standard) is the analytical standard of Norepinephrine (hydrochloride). This product is intended for research and analytical applications. Norepinephrine (Levarterenol; L-Noradrenaline) hydrochloride is a potent adrenergic receptor (AR) agonist. Norepinephrine activates α1, α2, β1 receptors[1][2][3][4].
    Norepinephrine hydrochloride (Standard)
  • HY-18207
    Fasidotril 135038-57-2 98%
    Fasidotril is a dual inhibitor of neprilysin and angiotensin-converting enzyme (ACE) for the potential research of hypertension and congestive heart failure (CHF).
    Fasidotril
  • HY-18277
    MK-7145 1255204-84-2 98%
    MK-7145 is a ROMK inhibitor, with an IC50 of 0.045 μM.
    MK-7145
  • HY-100292
    SL910102 144756-71-8 98%
    SL910102 is a nonpeptide angiotensin AT1 receptor antagonist.
    SL910102
  • HY-105218
    Ifetroban 143443-90-7 99.65%
    Ifetroban (BMS-180291) is an orally active antagonist of thromboxane A2 (TXA2) or prostaglandin H2 (PGH2) receptor. Ifetroban shows antiplatelet activity, and inhibits tumor cell migration without affecting cell proliferation. Ifetroban can be used for myocardial ischemia, hypertension, stroke, thrombosis, cardiomyopathy research.
    Ifetroban
  • HY-109562
    CCG258208 2055990-90-2 98%
    CCG258208 (GRK2-IN-1) is a potent and selective GRK2 (G protein-coupled receptor kinase 2) inhibitor (IC50=30 nM) while maintaining 230-fold selectivity over GRK5 (IC50=7.09 μM) and more than 2500-fold selectivity over GRK1 (IC50=87.3 μM), PKA, and ROCK1. CCG258208 can be used in heart failure research.
    CCG258208
  • HY-111516
    MGV354 98%
    MGV354 is a soluble guanylate cyclase (sGC) activator with EC50s of <0.5 nM, and 5 nM in CHO and GTM-3 E cells, respectively.
    MGV354
  • HY-111755
    Oral antiplatelet agent 1 2299200-91-0 98%
    Oral antiplatelet agent 1 is a potent P2Y12 receptor antagonist. Oral antiplatelet agent 1 exhibits excellent antiplatelet aggregation potency with an IC50 value of 2.94 μM as well as antithrombotic efficacy in a rat ferric chloride model. Oral antiplatelet agent 1 shows a superior safety profile than Clopidogrel (HY-15283) in a rat tail-bleeding model. Oral antiplatelet agent 1 can be used to research thromboembolic disorders.
    Oral antiplatelet agent 1
  • HY-112605
    sPLA2-X Inhibitor 31 2241025-50-1 98%
    sPLA2-X Inhibitor 31 is a selective secreted phospholipase A2 type X (sPLA2-X) inhibitor with IC50s of 26 nM, 310 nM, and 2230 nM for sPLA2-X, sPLA2-IIa, and sPLA2-V, respectively.
    sPLA2-X Inhibitor 31
  • HY-115876
    BTK-IN-5 2145152-06-1 98%
    BTK-IN-5 is a covalent BTK inhibitor for researching medical conditions such as cardiovascular diseases, respiratory diseases, inflammation, and diabetes.
    BTK-IN-5
  • HY-120088
    PF-06446846 1632250-49-7 98%
    PF-06446846 is an orally active proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. PF-06446846 directly and selectively inhibits translation of PCSK9 by stalling the 80S ribosome in the proximity of codon region.
    PF-06446846
  • HY-12778R
    Ivabradine metabolite N-Demethyl Ivabradine hydrochloride (Standard) 1246638-08-3
    Ivabradine metabolite N-Demethyl Ivabradine (hydrochloride) (Standard) is the analytical standard of Ivabradine metabolite N-Demethyl Ivabradine (hydrochloride). This product is intended for research and analytical applications. 0
    Ivabradine metabolite N-Demethyl Ivabradine hydrochloride (Standard)
  • HY-132303
    MK-8262 1432054-03-9 98%
    MK-8262 is an orally active and potent cholesteryl ester transfer protein (CETP) inhibitor with an IC50 of 53 nM and a log D of 5.3. MK-8262, a bistrifluoromethyl analogue, has the potential for coronary heart disease (CHD) correlated high-density lipoprotein (HDL) and low-density lipoprotein (LDL) research.
    MK-8262
  • HY-137446
    Mosliciguat 2231749-54-3 98%
    Mosliciguat is a guanylate cyclase activator.
    Mosliciguat
Cat. No. Product Name / Synonyms Application Reactivity